In Brief: Visx/Autonomous Technologies
This article was originally published in The Gray Sheet
Executive Summary
Visx/Autonomous Technologies: Enter patent license agreement under which Autonomous gains rights to certain Visx patents relating to laser vision correction outside of the U.S. As a result of the license, Visx' pending patent suit against Autonomous in the U.K. and an Autonomous suit against Visx in Canada ("The Gray Sheet" Nov. 4, 1996, In Brief) "will be dismissed," Visx says...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.